>
Calliditas Therapeutics AB logo

CALTX - Calliditas Therapeutics AB Share Price

SEK115 -1.0  -0.9%

Last Trade - 12:45pm

Sector
Healthcare
Size
Mid Cap
Market Cap £495.2m
Enterprise Value £414.0m
Revenue £74.7k
Position in Universe 483rd / 1829
Bullish
Bearish
Unlock CALTX Revenue
Momentum
Relative Strength (%)
1m -11.9%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 184.8 0.87 28.9 454.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Calliditas Therapeutics AB revenues decreased 100% toSEK874K. Net loss increased from SEK32.6M to SEK433.5M.Revenues reflect a decrease in demand for the Company'sproducts and services due to unfavorable market conditions.Higher net loss reflects Research & Development Expenseincrease of 61% to SEK241.4M (expense), AdministrationExpenses increase from SEK62.9M to SEK141.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CALTX Revenue Unlock CALTX Revenue

Net Income

CALTX Net Income Unlock CALTX Revenue

Normalised EPS

CALTX Normalised EPS Unlock CALTX Revenue

PE Ratio Range

CALTX PE Ratio Range Unlock CALTX Revenue

Dividend Yield Range

CALTX Dividend Yield Range Unlock CALTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CALTX EPS Forecasts Unlock CALTX Revenue
Profile Summary

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since June 29, 2018
No. of Shareholders: n/a
No. of Employees: 23
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 49,941,584
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CALTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CALTX
Upcoming Events for CALTX
Friday 25th June, 2021 Estimate
Calliditas Therapeutics AB Annual Shareholders Meeting
Frequently Asked Questions for Calliditas Therapeutics AB
What is the Calliditas Therapeutics AB share price?

As of 12:45pm, shares in Calliditas Therapeutics AB are trading at SEK115, giving the company a market capitalisation of £495.2m. This share price information is delayed by 15 minutes.

How has the Calliditas Therapeutics AB share price performed this year?

Shares in Calliditas Therapeutics AB are currently trading at SEK115 and the price has moved by 33.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Calliditas Therapeutics AB price has moved by 4.19% over the past year.

What are the analyst and broker recommendations for Calliditas Therapeutics AB?

Of the analysts with advisory recommendations for Calliditas Therapeutics AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Calliditas Therapeutics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Calliditas Therapeutics AB next release its financial results?

Calliditas Therapeutics AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Calliditas Therapeutics AB dividend yield?

Calliditas Therapeutics AB does not currently pay a dividend.

Does Calliditas Therapeutics AB pay a dividend?

Calliditas Therapeutics AB does not currently pay a dividend.

When does Calliditas Therapeutics AB next pay dividends?

Calliditas Therapeutics AB does not currently pay a dividend.

How do I buy Calliditas Therapeutics AB shares?

To buy shares in Calliditas Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Calliditas Therapeutics AB?

Shares in Calliditas Therapeutics AB are currently trading at SEK115, giving the company a market capitalisation of £495.2m.

Where are Calliditas Therapeutics AB shares listed? Where are Calliditas Therapeutics AB shares listed?

Here are the trading details for Calliditas Therapeutics AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: CALTX
What kind of share is Calliditas Therapeutics AB?

Based on an overall assessment of its quality, value and momentum, Calliditas Therapeutics AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Calliditas Therapeutics AB share price forecast 2021?

Shares in Calliditas Therapeutics AB are currently priced at SEK115. At that level they are trading at 89.66% discount to the analyst consensus target price of 0.00.

Analysts covering Calliditas Therapeutics AB currently have a consensus Earnings Per Share (EPS) forecast of -11.72 for the next financial year.

How can I tell whether the Calliditas Therapeutics AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calliditas Therapeutics AB. Over the past six months, the relative strength of its shares against the market has been -19.05%. At the current price of SEK115, shares in Calliditas Therapeutics AB are trading at -3.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Calliditas Therapeutics AB PE Ratio?

We were not able to find PE ratio data for Calliditas Therapeutics AB.

Who are the key directors of Calliditas Therapeutics AB?

Calliditas Therapeutics AB's management team is headed by:

Bengt Julander - NED
Lennart Hansson - NED
Thomas Eklund - NED
Hilde Furberg - NED
Elmar Schnee - CHM
Diane Parks - NED
Renee Aguiar-Lucander - CEO
Fredrik Johansson - CFO
Richard Philipson - OTH
Frank Bringstrup - VPR
Katayoun Welin-Berger - VOP
Jonathan Schur - GCN
Warren Brooks - VPR
Teona Johnson - OTH
David Ferraro - OTH
Who are the major shareholders of Calliditas Therapeutics AB?

Here are the top five shareholders of Calliditas Therapeutics AB based on the size of their shareholding:

Similar to CALTX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.